Trials / Completed
CompletedNCT00310518
Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the overall response rate (ORR) of persistent, recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 501 |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2006-04-04
- Last updated
- 2009-04-29
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00310518. Inclusion in this directory is not an endorsement.